Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/31456
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2023-03-09T07:50:44Z | - |
dc.date.available | 2023-03-09T07:50:44Z | - |
dc.date.issued | 2007-07-30 | - |
dc.identifier.citation | Akkaya, C. vd. (2007). "Retrospective database analysis on the effectiveness of typical and atypical antipsychotic drugs in an outpatient clinic setting". Human Psychopharmacology, 22(8), 515-528. | en_US |
dc.identifier.issn | 0885-6222 | - |
dc.identifier.issn | 1099-1077 | - |
dc.identifier.uri | https://doi.org/10.1002/hup.882 | - |
dc.identifier.uri | https://onlinelibrary.wiley.com/doi/10.1002/hup.882 | - |
dc.identifier.uri | http://hdl.handle.net/11452/31456 | - |
dc.description.abstract | Objective To report the outcomes of a retrospective database analysis to compare the effectiveness of atypical and typical antipsychotic drugs. Methods Medical records of patients admitted to the psychiatry outpatient clinic between January 1998 and October 2005 were retrospectively reviewed. Data obtained from patient records were noted on a special form assessing four aspects of the treatment history: socio-demographic features, disease characteristics, initial treatment at the time of admission, and course of treatment. Patient groups (typical/atypical and Risperidone/Haloperidol/Olanzapine) were compared for time to all-cause medication discontinuation and rate of discontinuation. Results There was no statistically significant difference in the duration of treatment between patients using atypical (n=150) and typical (n=124) antipsychotics. The duration of treatment was significantly longer in patients on Haloperidol (n=91) compared with those on Risperidone (n=63). Rates of discontinuation over 18 months were 59.3% for patients on atypical antipsychotics and 57.3% for those on typical antipsychotics, and 68.3% for patients on Risperidone, 51.6% for patients on Haloperidol and 54.3% for patients on Olanzapine. Conclusion Despite our hypothesis patients with chronic schizophrenia discontinued their atypical and typical antipsychotics, at a high rate with no significant difference indicating substantial limitations in the effectiveness of these drugs. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Wiley | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Schizophrenia | en_US |
dc.subject | Database analysis | en_US |
dc.subject | Antipsychotic treatment | en_US |
dc.subject | Effectiveness | en_US |
dc.subject | New-generation antipsychotics | en_US |
dc.subject | Controlled-trials | en_US |
dc.subject | 2nd-generation antipsychotics | en_US |
dc.subject | Rehospitalization rates | en_US |
dc.subject | Chronic-schizophreniarandomized-trials | en_US |
dc.subject | Medication | en_US |
dc.subject | Catie | en_US |
dc.subject | Metaanalysis | en_US |
dc.subject | Therapy | en_US |
dc.subject | Neurosciences & neurology | en_US |
dc.subject | Pharmacology & pharmacy | en_US |
dc.subject | Psychiatry | en_US |
dc.subject | Psychology | en_US |
dc.subject.mesh | Adolescent | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Aged, 80 and over | en_US |
dc.subject.mesh | Antipsychotic agents | en_US |
dc.subject.mesh | Benzodiazepines | en_US |
dc.subject.mesh | Databases, factual | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Haloperidol | en_US |
dc.subject.mesh | Hospitals, university | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Long-term care | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle aged | en_US |
dc.subject.mesh | Outpatient clinics, hospital | en_US |
dc.subject.mesh | Retrospective studies | en_US |
dc.subject.mesh | Risperidone | en_US |
dc.subject.mesh | Schizophrenia | en_US |
dc.subject.mesh | Treatment outcome | en_US |
dc.subject.mesh | Treatment refusal | en_US |
dc.subject.mesh | Turkey | en_US |
dc.title | Retrospective database analysis on the effectiveness of typical and atypical antipsychotic drugs in an outpatient clinic setting | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000252305600003 | tr_TR |
dc.identifier.scopus | 2-s2.0-37849005650 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Psikiyatri Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı. | tr_TR |
dc.identifier.startpage | 515 | tr_TR |
dc.identifier.endpage | 528 | tr_TR |
dc.identifier.volume | 22 | tr_TR |
dc.identifier.issue | 8 | tr_TR |
dc.relation.journal | Human Psychopharmacology | en_US |
dc.contributor.buuauthor | Akkaya, Cengiz | - |
dc.contributor.buuauthor | Sarandöl, Aslı | - |
dc.contributor.buuauthor | Cangür, Şengül | - |
dc.contributor.buuauthor | Kırlı, Selçuk | - |
dc.identifier.pubmed | 17868197 | tr_TR |
dc.subject.wos | Clinical neurology | en_US |
dc.subject.wos | Psychology | en_US |
dc.subject.wos | Pharmacology & pharmacy | en_US |
dc.subject.wos | Psychiatry | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | PubMed | en_US |
dc.wos.quartile | Q2 (Clinical neurology) | en_US |
dc.wos.quartile | Q2 (Psychology) | en_US |
dc.wos.quartile | Q3 | en_US |
dc.contributor.scopusid | 2-s2.0-37849005650 | tr_TR |
dc.subject.scopus | Clozapine; Neuroleptic Agent; Schizophrenia | en_US |
dc.subject.emtree | Amisulpride | en_US |
dc.subject.emtree | Antidepressant agent | en_US |
dc.subject.emtree | Anxiolytic agent | en_US |
dc.subject.emtree | Atypical antipsychotic agent | en_US |
dc.subject.emtree | Carbamazepine | en_US |
dc.subject.emtree | Chlorpromazine | en_US |
dc.subject.emtree | Cholinergic receptor blocking agent | en_US |
dc.subject.emtree | Clozapine | en_US |
dc.subject.emtree | Flupentixol | en_US |
dc.subject.emtree | Fluphenazine | en_US |
dc.subject.emtree | Haloperidol | en_US |
dc.subject.emtree | Lithium salt | en_US |
dc.subject.emtree | Long acting drug | en_US |
dc.subject.emtree | Mood stabilizer | en_US |
dc.subject.emtree | Neuroleptic agent | en_US |
dc.subject.emtree | Olanzapine | en_US |
dc.subject.emtree | Pimozide | en_US |
dc.subject.emtree | Quetiapine | en_US |
dc.subject.emtree | Risperidone | en_US |
dc.subject.emtree | Sulpride | en_US |
dc.subject.emtree | Thioridazine | en_US |
dc.subject.emtree | Tranquilizer | en_US |
dc.subject.emtree | Trifluoperazine | en_US |
dc.subject.emtree | Unclassified drug | en_US |
dc.subject.emtree | Valproic acid | en_US |
dc.subject.emtree | Zuclopenthixol | en_US |
dc.subject.emtree | Adolescent | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Aged | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Clinical feature | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Demography | en_US |
dc.subject.emtree | Drug efficacy | en_US |
dc.subject.emtree | Drug withdrawal | en_US |
dc.subject.emtree | Extrapyramidal syndrome | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Hospital admission | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Major clinical study | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Medical record review | en_US |
dc.subject.emtree | Nausea and vomiting | en_US |
dc.subject.emtree | Outpatient | en_US |
dc.subject.emtree | Patient compliance | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Retrospective study | en_US |
dc.subject.emtree | Schizophrenia | en_US |
dc.subject.emtree | Sedation | en_US |
dc.subject.emtree | Side effect | en_US |
dc.subject.emtree | Social aspect | en_US |
dc.subject.emtree | Statistical significance | en_US |
dc.subject.emtree | Treatment duration | en_US |
dc.subject.emtree | Treatment outcome | en_US |
dc.subject.emtree | Weight gain | en_US |
Appears in Collections: | PubMed Scopus Web of Science |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.